Format

Send to

Choose Destination
Lung Cancer. 2014 Feb;83(2):300-1. doi: 10.1016/j.lungcan.2013.11.018. Epub 2013 Dec 1.

Temsirolimus therapy in a patient with lung adenocarcinoma harboring an FBXW7 mutation.

Author information

1
University of Pittsburgh Cancer Institute, University of Pittsburgh, School of Medicine/Hematology-Oncology, Lung and Thoracic Malignancies Program, Pittsburgh, PA 15232, United States. Electronic address: VillaruzL@upmc.edu.
2
University of Pittsburgh Cancer Institute, University of Pittsburgh, School of Medicine/Hematology-Oncology, Lung and Thoracic Malignancies Program, Pittsburgh, PA 15232, United States.

Abstract

We report the identification of an FBXW7 mutation in a patient with adenocarcinoma of the lung, whose tumor had previously been shown to be EGFR and ALK wild type and who had previously progressed on multiple lines of systemic therapy. She experienced both clinical and radiographic benefit from treatment with the mTOR inhibitor temsirolimus.

KEYWORDS:

FBXW7 mutation; Lung adenocarcinoma; Next generation sequencing; Temsirolimus; mTOR inhibitor

PMID:
24360397
PMCID:
PMC4836187
DOI:
10.1016/j.lungcan.2013.11.018
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center